During the last decade, several research groups have succeeded in recruiting to randomized controlled trials and reported the outcome of the use of stereotactic ablative radiotherapy (SABR) in patients with oligometastatic disease (OMD) [1–6]. Large variations exist in reported outcomes among published series, and patient selection plays an important part in this variation [7]. Evidence indicates that treating lesions with a radiotherapeutic definitive intent in the abdominal region is associated with worse outcomes, including increased toxicity and decreased local control rates compared to other treatment sites [8–11].